John Francis Crowley

Who is John Francis Crowley?

Mr. Crowley became president and CEO of Amicus in January 2005, having

served as a director since 2004. Previously he was founding president

and CEO of Orexigen Therapeutics. Preceding Orexigen, Mr. Crowley was

senior vice president at Genzyme Therapeutics, a position he assumed

after overseeing the sale of Novazyme Pharmaceuticals to Genzyme in

September 2001. Mr. Crowley was the founding president and CEO of

Novazyme that was developing a novel treatment for Pompe disease. He

previously served in several senior management roles with the

Bristol-Myers Squibb Company (BMS), including director of the Executive

Committee for the U.S. Medicines Group, director of Business Strategy

for the U.S. Pharmaceuticals Group, and director of U.S. Area Marketing

for the Neuroscience and Infectious Disease Division. Preceding his

experience at BMS, Mr. Crowley worked as a business strategy consultant

for Marakon Associates. Mr. Crowley began his professional career as a

litigation associate in the Health Care Practice Group of the

Indianapolis-based law firm of Bingham, Summers, Welsh Spilman.Mr.

Crowley is involved with several charitable and community

organizations, including serving as president of the National Tay-Sachs

and Allied Diseases Association. He is also on the Research Advisory

Board of the national Muscular Dystrophy Association and the Board of

Directors of St. Peter's University Hospital. Mr. Crowley's involvement

with biotechnology stems from the 1998 diagnosis of two of his children

with Pompe disease - a fatal neuromuscular disorder. Mr. Crowley and

his family have been featured on the cover of The Wall Street Journal

and on The Today Show, CNBC and The Paula Zahn Show.Mr. Crowley is a commissioned officer in the United States Navy Reserve (active).Mr.

Crowley earned his B.S. degree in Foreign Service from Georgetown

University's School of Foreign Service, his J.D. from the University of

Notre Dame Law School and his M.B.A. from Harvard Business School.